Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard University, New Delhi,India.
PLoS One. 2019 Aug 15;14(8):e0220920. doi: 10.1371/journal.pone.0220920. eCollection 2019.
Xanthone derivatives have been reported to possess a wide range of biological properties. In effort to search new effective antihypertensive compounds, we have synthesizednovel xanthone derivatives (xanthonoxypropanolamines) and got patent for these compounds (The Patent Office, Government of India, S. No.: 011-016308, Patent No.: 250538).
In the present work, we attempted to establish the antihypertensive activity, toxicity and molecular docking study forthese newly synthesized compounds (1a, 1b and 2).
The preliminary antihypertensive screening was performed by administering synthesized compounds and standard drugs intraperitonially and orally into wistar rats. The change in systolic, diastolic and the mean blood pressure before and after the treatment of the drugs was measured on a Digital LE-S100 Blood Pressure Meter by Tail-cuff method non-invasively. Toxicity studies were carried out after oral administration of synthesized compounds to rats at doses of 25, 50, and 100mg/kg. The serum samples were tested for different toxicity parameters such as liver function test, kidney function test etc. The docking simulations of all the compounds were performed using Maestro, version 9.4 implemented from Schrodinger software suite.
The result showed that the compound 1a, 1b and 2 have greater antihypertensive activity with almost equal or less toxicity profile in comparison to standard drug Propranolol and Atenolol. The docking score for the compound 1b was found -9.1 while for compound 1a and 2 were found -8.7 and -8.6 respectively.
These novel compounds i.e. 1a, 1b, and 2 have greater antihypertensive activity in comparison to standard drugs Propranolol and Atenolol. All these compounds do not have any toxicity.
已报道黄烷酮衍生物具有广泛的生物活性。为了寻找新的有效抗高血压化合物,我们合成了新型黄烷酮衍生物(黄烷酮氧基丙醇胺),并为这些化合物获得了专利(印度政府专利局,编号:011-016308,专利号:250538)。
在本工作中,我们试图确定这些新合成化合物(1a、1b 和 2)的抗高血压活性、毒性和分子对接研究。
通过腹膜内和口服给予合成化合物和标准药物,初步进行抗高血压筛选,在 Digital LE-S100 血压计上通过尾套法无创测量药物治疗前后收缩压、舒张压和平均血压的变化。以 25、50 和 100mg/kg 的剂量口服给予合成化合物后,进行毒性研究。检测血清样本的不同毒性参数,如肝功能试验、肾功能试验等。使用 Maestro,版本 9.4,从 Schrodinger 软件套件中执行,对所有化合物进行对接模拟。
结果表明,与标准药物普萘洛尔和阿替洛尔相比,化合物 1a、1b 和 2 具有更大的降压活性,且毒性谱几乎相等或更低。化合物 1b 的对接评分为-9.1,而化合物 1a 和 2 的对接评分分别为-8.7 和-8.6。
与标准药物普萘洛尔和阿替洛尔相比,这些新型化合物 1a、1b 和 2 具有更大的降压活性。所有这些化合物均无毒性。